Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Indirubin 3'-monoxime, from a Chinese traditional herbal formula, suppresses viremia in humanized mice infected with multidrug-resistant HIV.

Heredia A, Natesan S, Le NM, Medina-Moreno S, Zapata JC, Reitz M, Bryant J, Redfield RR.

AIDS Res Hum Retroviruses. 2014 May;30(5):403-6. doi: 10.1089/AID.2013.0249. Epub 2014 Feb 7. No abstract available.

PMID:
24401082
[PubMed - in process]
2.

Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.

Zhen Y, Sørensen V, Jin Y, Suo Z, Wiedłocha A.

Oncogene. 2007 Sep 27;26(44):6372-85. Epub 2007 May 28.

PMID:
17533378
[PubMed - indexed for MEDLINE]
3.

Indirubin-3'-monoxime, a derivative of a Chinese anti-leukemia medicine, inhibits Notch1 signaling.

Lee MJ, Kim MY, Mo JS, Ann EJ, Seo MS, Hong JA, Kim YC, Park HS.

Cancer Lett. 2008 Jul 8;265(2):215-25. doi: 10.1016/j.canlet.2008.02.013. Epub 2008 Mar 17.

PMID:
18343569
[PubMed - indexed for MEDLINE]
4.

Indirubin-3'-monoxime, a CDK inhibitor induces growth inhibition and apoptosis-independent up-regulation of survivin in transitional cell cancer.

Perabo FG, Frössler C, Landwehrs G, Schmidt DH, von Rücker A, Wirger A, Müller SC.

Anticancer Res. 2006 May-Jun;26(3A):2129-35.

PMID:
16827155
[PubMed - indexed for MEDLINE]
Free Article
5.

Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest.

Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L.

Oncogene. 2001 Jun 28;20(29):3786-97.

PMID:
11439342
[PubMed - indexed for MEDLINE]
Free Article
6.

Antiproliferative and apoptosis inducing effects of indirubin-3'-monoxime in renal cell cancer cells.

Perabo FG, Landwehrs G, Frössler C, Schmidt DH, Mueller SC.

Urol Oncol. 2011 Nov-Dec;29(6):815-20. doi: 10.1016/j.urolonc.2009.10.005. Epub 2009 Nov 27.

PMID:
19945313
[PubMed - indexed for MEDLINE]
7.
8.

[Therapeutic effects of traditional Chinese herbal formula with Smilax glabra on mice's lead poisoning].

Xia DZ, Wang HM, Yang Q, Jiang LQ, Xia M.

Zhong Yao Cai. 2009 Mar;32(3):404-6. Chinese.

PMID:
19565723
[PubMed - indexed for MEDLINE]
9.

Effect of indirubin-3-monoxime against lung cancer as evaluated by histological and transmission electron microscopic studies.

Ravichandran K, Pal A, Ravichandran R.

Microsc Res Tech. 2010 Oct;73(11):1053-8. doi: 10.1002/jemt.20832.

PMID:
20169620
[PubMed - indexed for MEDLINE]
10.

Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication.

Heredia A, Davis C, Bamba D, Le N, Gwarzo MY, Sadowska M, Gallo RC, Redfield RR.

AIDS. 2005 Dec 2;19(18):2087-95.

PMID:
16284457
[PubMed - indexed for MEDLINE]
11.

Indirubin-3'-monoxime promotes autophagic and apoptotic death in JM1 human acute lymphoblastic leukemia cells and K562 human chronic myelogenous leukemia cells.

Lee MY, Liu YW, Chen MH, Wu JY, Ho HY, Wang QF, Chuang JJ.

Oncol Rep. 2013 May;29(5):2072-8. doi: 10.3892/or.2013.2334. Epub 2013 Mar 6.

PMID:
23468088
[PubMed - indexed for MEDLINE]
12.

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G, Meijer L.

Nat Cell Biol. 1999 May;1(1):60-7.

PMID:
10559866
[PubMed - indexed for MEDLINE]
13.

An indirubin derivative, indirubin-3'-monoxime suppresses oral cancer tumorigenesis through the downregulation of survivin.

Lo WY, Chang NW.

PLoS One. 2013 Aug 13;8(8):e70198. doi: 10.1371/journal.pone.0070198. eCollection 2013.

PMID:
23967071
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

[Framework and practice of network-based studies for Chinese herbal formula].

Li S.

Zhong Xi Yi Jie He Xue Bao. 2007 Sep;5(5):489-93. Chinese.

PMID:
17854545
[PubMed - indexed for MEDLINE]
Free Article
15.

Indirubin-3'-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis.

Kim JK, Shin EK, Kang YH, Park JH.

J Cell Biochem. 2011 May;112(5):1384-91. doi: 10.1002/jcb.23055.

PMID:
21337385
[PubMed - indexed for MEDLINE]
16.

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, Greengard P, Biernat J, Wu YZ, Mandelkow EM, Eisenbrand G, Meijer L.

J Biol Chem. 2001 Jan 5;276(1):251-60.

PMID:
11013232
[PubMed - indexed for MEDLINE]
Free Article
17.

GBV-C viremia and clinical events in advanced HIV infection.

Sahni H, Kirkwood K, Kyriakides TC, Stapleton J, Brown ST, Holodniy M; OPTIMA Study Team.

J Med Virol. 2014 Mar;86(3):426-32. doi: 10.1002/jmv.23845. Epub 2013 Nov 19.

PMID:
24249700
[PubMed - indexed for MEDLINE]
18.

Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells.

Marko D, Schätzle S, Friedel A, Genzlinger A, Zankl H, Meijer L, Eisenbrand G.

Br J Cancer. 2001 Jan;84(2):283-9.

PMID:
11161389
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Activation of P-TEFb at sites of dual HIV/TB infection, and inhibition of MTB-induced HIV transcriptional activation by the inhibitor of CDK9, Indirubin-3'-monoxime.

Toossi Z, Wu M, Hirsch CS, Mayanja-Kizza H, Baseke J, Aung H, Canaday DH, Fujinaga K.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):182-7. doi: 10.1089/AID.2010.0211. Epub 2011 May 6.

PMID:
21453127
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD, Dimitrov DS, Nussenzweig MC, Martin MA.

Nature. 2013 Nov 14;503(7475):277-80. doi: 10.1038/nature12746. Epub 2013 Oct 30.

PMID:
24172896
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk